Identification of pre-diabetic individuals with decreased functional ß-cell mass is essential for the prevention of diabetes. However, in vivo detection of early asymptomatic ß-cell defect remains unsuccessful. Metabolomics emerged as a powerful tool in providing read-outs of early disease states before clinical manifestation. We aimed at identifying novel plasma biomarkers for loss of functional ß-cell mass in the asymptomatic pre-diabetic stage. Non-targeted and targeted metabolomics were applied on both lean ß-Phb2 -/mice (ß-cell-specific prohibitin-2 knockout) and obese db/db mice (leptin receptor mutant), two distinct mouse models requiring neither chemical nor diet treatments to induce spontaneous decline of functional ß-cell mass promoting progressive diabetes development.
INTRODUCTION
Both type 1 and type 2 diabetes (T2D) are a chronic diseases primarily characterized by ß-cell defect.
While the former is an autoimmune disease resulting in the inexorable destruction of the ß-cells (1), the latter is usually associated with obesity-induced insulin resistance eventually leading to ß-cell failure that prompts diabetes (2; 3) . Indeed, insufficient insulin secretion has emerged as the determining factor for the onset of T2D (4; 5) . Although loss of ß-cell function and mass both contribute to impaired insulin secretion (6; 7), these two parameters are not well correlated and their relative contribution to T2D pathogenesis remains a subject of debate (8; 9) . Identification of robust and sensitive in vivo biomarkers that could reflect the integrated assessment of ß-cell function and mass, i.e. the functional ß-cell mass, would be essential for the identification of high-risk, but yet asymptomatic, individuals for the prevention of diabetes.
Metabolomics is a powerful method to measure subtle biochemical changes caused by underlying pathologies (10; 11) . The main metabolites consistently appearing in human T2D studies include branched-chain amino acids (BCAAs) (12; 13) , aromatic amino acids (13) , fructose (14; 15), mannose (14; 16) , α-hydroxybutyrate (17; 18) and phospholipids (18) (19) (20) . Most of these identified T2D-related metabolites are associated with insulin resistance and obesity (21; 22) rather than the direct alteration of the ß-cells. This is partially due to the fact that the clinical practice for diabetes detection, such as fasting glucose and glucose tolerance test, cannot efficiently discriminate the respective contributions of insulin resistance versus insulin secretion (23; 24). Therefore, we still lack biomarkers reflecting the loss of the functional ß-cell mass as the triggering event.
The main obstacle for the identification of biomarkers that would be specific for early ß-cell defects is the scarce availability of pancreas samples from pre-diabetic subjects. By essence, one cannot study isolated human pancreas from an individual who would later eventually develop T2D; likewise pancreatic tissues are only available upon autopsy or invasive surgery (25). Animal models are useful surrogates but typically require special diets or drug injections to induce diabetes, which may generate confounding factors. To address these issues, we used two mouse models, i.e. the ß-cell-specific Prohibitin-2 knockout (ß-Phb2 -/-) mice (26) and the leptin receptor-deficient mice (db/db) mice (27). 4 Both mouse models exhibit progressive ß-cell failure and diabetes development, while the genetic cause of the disease differs. Deletion of Phb2 in the ß-cells causes mitochondrial alterations and ß-cell dysfunction, then apoptosis and a progressive decline in the ß-cell mass starting at 4 weeks of age resulting in the onset of diabetes in ß-Phb2 -/mice at 6 weeks of age (26). The db/db mice carry a single-gene spontaneous mutation in the leptin receptor that leads to hyperphagia and obesity (28), diabetes appearing approximately at the age of 8 weeks (29) when the decline in functional ß-cells results in the failure to compensate for insulin resistance (30). In both mouse models, the critical event triggering diabetes, subsequently uncovered by hyperglycemia, is the loss of a critical mass of functional ß-cells, similarly to human subjects (5; 31) . Using non-targeted and targeted metabolomics, we profiled the liver and plasma metabolome of ß-Phb2 -/and db/db mice from the earliest postweaning age (4 weeks) to diabetes onset and later. Along with the assessment of the ß-cell mass, the simultaneous measurements of hundreds of metabolites (32) led to the identification of common changing metabolites. Ultimately, we have found a shared metabolite among the mouse models, which levels linearly correlate with the decline of the functional ß-cell mass already in the asymptomatic pre-diabetic state.
RESEARCH DESIGN AND METHODS

Animals
All animal experiments were conducted at the University of Geneva Medical Centre with the approval by the animal care and experimentation authorities of the Canton of Geneva (#GE/128/15). Mice were maintained on a 12-h dark/light cycle with water and food ad libitum and genotyped using primers listed in Supplementary Table S1 . Since the phenotype of ß-Phb2 -/mice is similar between males and females (26), only males were used for experiments and the age of the mice is specified for each experiment. All ß-Phb2 -/and Phb2 fl/fl mice were generated as previously described (26) and maintained on a mixed genetic background (C57BL/6J × 129/Sv) to avoid inbred strain-specific phenotypes. BKS.Cg-Dock7m+/+Lepr db /J mice (db/db and heterozygous db/+ mice as controls) were purchased from Charles River, Italy. 6 were collected, and islets were re-suspended in acid ethanol for determination of insulin contents.
Insulin in supernatants and extracted islets was measured using radioimmunoassay (Millipore).
Metabolome extraction
The metabolome extractions were performed from a 50-100 mg of frozen liver. The samples were initially homogenized by TissueLyser II (Qiagen) in 1 mL cold 70% ethanol. Extraction was continued with addition of 7 mL hot 70% ethanol (75°C) for 2 min with thorough mixing every 30 sec, followed by removal of cell debris by centrifugation. Extracts were stored at -20°C until mass spectrometry analysis. Plasma was extracted by adding 90 L of 80% methanol to 10 L volume of plasma, followed by thorough vortex mixing. After 1 h incubation at 4°C, centrifugation was done at maximum speed for 10 min and supernatant was used for mass spectrometry measurement.
Non-targeted metabolomics
Untargeted metabolomics was performed by flow injection analysis on a 6550 Agilent QTOF instrument as described (32). Briefly, profile spectra were recorded in negative ionization from m/z 50 to 1000 mode at 4 GHz high-resolution mode. Ion annotation was based on accurate masses using a tolerance of 0.001 amu and KEGG mmu database, accounting for -H + and Fions, sodium and potassium adducts, and heavy isotopes. The further data analysis involved calculating log 2 fold changes between different groups (e.g. knockout vs control at week 4), with statistical significance calculated by two-sample Student's t-test, additionally corrected for multiple testing and expressed as q-values (37). The data analysis was performed in MATLAB (The MathWorks).
For targeted metabolomics by LC-MS, polar metabolome extracts were dried and re-suspended in deionized water. To adjust for the differences in tissue sample weight, dried samples were resuspended in 10 µL of deionized water per 1 µg tissue. Centrifuged cold supernatant aliquots of 10 µL were injected into a Waters Acquity UPLC (Waters Corporation, Milford, MA) with a Waters Acquity T3 column coupled to a Thermo TSQ Quantum Ultra triple quadrupole instrument (Thermo Fisher Scientific) with negative-mode electrospray ionization. Gradient of two mobile phases (A) 10 mmol/L tributylamine, 15 mmol/L acetic acid and 5% (v/v) methanol, and (B) 2-propanol was used 8 from, Sigma Aldrich GmbH (Steinheim, Germany), namely 1,5-anhydro-D-glucitol (A7165, CAS 154-58-5), D-(+)-fucose (F8150, CAS 3615-37-0) and L-(-)-fucose (F2252, CAS 2438-80-4). D-/ Lstereo isomers were not distinguished by this method. Identification of 1,5-anhydro-D-glucitol was supported by earlier reports (45) and by exact masses (± 5 mDa) of the molecular ion (M + ), proton adducts (M+H + ) and M-CH 3 + fragments that were observed by GC/APCI-qTOF-MS.
All mass features of an experiment were normalized by sample fresh weight or volume (plasma) and internal standard and subsequently maximum scaled (%) for visualization of relative concentration changes.
Machine learning algorithm
The machine learning method to classify the disease state consists of a composition of a preprocessing step and a classification step. For the pre-processing step, we tested the following algorithms: Principal Component Analysis (PCA), L1-regularized Logistic Regression and correlation thresholding, which consists of ranking the metabolites according to their Pearson's sample correlation coefficient and selecting those with highest correlation coefficient (the number of chosen features is a parameter of the algorithm, coded in python). For the classification step, we tested linear discriminant analysis, L1-regularized Logistic Regression, Gradient Boosting, and Random Forests (46). After testing all the possible combinations of pre-processing and classification algorithms listed above, we selected the one yielding the best score on a leave-20-out cross validation (CV) procedure repeated 100 times. Overall, the percentage of sampling data into validation sets is 18% and 28% of the total dataset for ß-Phb2 -/and db/db mice, respectively. Each time, the validation set was resampled exclusively from the set of metabolomics profiles corresponding to the pre-diabetic stage.
The whole machine learning pipeline was coded in python, making extensive use of the "sklearn" package (47). The latest version of the program used for this analysis is available for download (https://github.com/agazzian/ml_project).
The best CV scores were consistently obtained by combining a correlation thresholding method for the pre-processing step with Random Forests algorithm for the classification step. The metabolites were finally ranked according to their importance in the classification process (attribute 10 weeks of age) and at diabetes onset (8 weeks of age), Figure 1E . The adipose tissue was much higher in db/db mice versus their controls at all the examined time points ( Figure 1F ).
Islet morphology and ß-cell mass in ß-Phb2 -/mice
Before the appearance of symptoms, the disease development from pre-diabetes to diabetes was accompanied by marked changes in the islet morphology of ß-Phb2 -/mice. There was a gradual decrease of insulin-positive cells and intrusion of glucagon-positive cells within the core of the islets (Figure 2A ). Notwithstanding ß-Phb2 -/mice of 4 and 5 weeks of age exhibited euglycemia ( Figure   1A ), quantitative analysis revealed a clear reduction (58-64%) of their ß-cell mass compared to controls ( Figures 2B, C) . This correlated with severely impaired glucose-stimulated insulin secretion tested on islets isolated from 4-week old ß-Phb2 -/mice (26). At the age of 6 weeks, the observed 68% reduction of the ß-cell mass was then associated with hyperglycemia ( Figure 1A) . Neither circulating C-peptide ( Figure 2D ) nor HOMA-IR ( Figure 2E ) could reflect the reduction of ß-cells before the appearance of hyperglycemia. Of note, at 10 weeks of age the C-peptide was undetectable in ß-Phb2 -/mice (data not shown). Therefore, ß-Phb2 -/mice present asymptomatic early-onset reduction of the ßcell mass before the appearance of hyperglycemia at the age of 6 weeks. This indicates a threshold around one third of the ß-cell mass for maintenance of euglycemia in such non-obese animals.
Islet morphology and ß-cell mass in db/db mice
As opposed to ß-Phb2 -/mice, db/db mice preserved their insulin-positive cells during diabetes development ( Figure 3A) . The ß-cell mass of db/db mice doubled from the age of 4 to 8 weeks and was significantly higher versus their controls at all examined time points ( Figure 3B , C). Consistent with the ß-cell mass, insulin contents per islet increased in db/db mice compared to db/+ controls at 4 and 8 weeks of age (35.0±3.7 versus 18.5±2.4 and 48.4±2.5 versus 14.6±3.8 ng/islet, respectively), along with higher circulating C-peptide ( Figure 3D ). In parallel, the insulin secretory responses on isolated islets from db/db mice dramatically deteriorated as diabetes developed ( Supplementary Table   4 ). At the age of 4 weeks, db/db mice exhibited similar glucose-stimulated insulin secretion compared with the controls. However, upon appearance of hyperglycaemia at 8 weeks, db/db mice presented a sharp decline of ß-cell function as reflected by a ~80% reduction of glucose-stimulated insulin 12 We analysed the metabolome with a special focus on amino acids and carbohydrate metabolism ( Figure 4C ). The most consistent diabetes-related metabolites from human T2D studies are the BCAAs, i.e. valine, leucine and isoleucine (12) (13) (14) , although their cause-effect relationship with diabetes per se remains unclear. BCAAs have been reported to increase in plasma years before diabetes diagnosis (13; 14) , probably contributed by obesity-related insulin resistance, therefore not reflecting ß-cell failure. In the plasma of ß-Phb2 -/mice, we found modest increase of BCAAs at the early pre-diabetic stage (4 weeks) and a more pronounced increase upon severe diabetes (10 weeks), which might be due to sarcopenia associated with cachectic state (Figure 1B, C) . In the plasma of fatty db/db mice ( Figure 1E , F), BCAAs showed marked increases at the early pre-diabetic stage (4 weeks), consistent with their association with insulin resistance (49). Apart from BCAAs, two of the aromatic amino acids, tyrosine and phenylalanine, have been positively associated with diabetes (13; 19 ). Similar to the pattern we observed with BCAAs, the increment of plasma aromatic amino acids was higher in db/db mice compared with ß-Phb2 -/mice during the pre-diabetic stage (4 weeks).
Regarding carbohydrate metabolites analysed by FIA-TOF-MS ( Figure 4C ), hexose sugars (e.g. glucose, mannose, fructose), denoted as Glucose (m/z ~179.056), increased in the plasma of both mouse models as diabetes progressed. Interestingly, in the liver of db/db mice, the increment of hexose sugars paralleled diabetes development, which could be explained by both higher food intake and increased endogenous glucose production caused by insulin resistance. On the contrary, hexose sugars remained unchanged in the liver of ß-Phb2 -/mice, except for a slight increase at diabetes onset (6 weeks) . Another striking difference between these two mouse models was the alteration in hepatic tricarboxylic acid (TCA) cycle at the pre-diabetic stage (4 weeks). In the liver of ß-Phb2 -/mice, the TCA cycle intermediates fumarate, succinate and malate slightly increased at the age of 4 weeks. This observation was further substantiated by targeted metabolomics using LC-MS (Supplementary Figure   S1 ). In db/db liver, fumarate, succinate, malate and citrate dramatically decreased ( Figure 4C ), suggesting important hepatic cataplerosis not compensated by the replenishment of the TCA cycle, i.e. anaplerosis. Malate and citrate exit the TCA cycle to fuel gluconeogenesis and lipogenesis, respectively, potentially contributing to the early-onset insulin resistance in db/db mice. In parallel, 15 the pre-diabetic stage (6 weeks) and remained lower compared to controls when mice became hyperglycaemic ( Figure 7C ). Thus, as opposed to its isomer 1,5-anhydroglucitol, fucose levels did not correlate with ß-cell failure.
In conclusion, both ß-Phb2 -/and db/db mouse models exhibited early changes specifically in the deoxyhexose 1,5-anhydroglucitol, in association with the development of diabetes triggered by a decline of the functional ß-cell mass.
DISCUSSION
A sensitive and robust biomarker of the functional ß-cell mass is an unmet medical need. To date, non-invasive imaging of total ß-cell mass is not yet available at the clinical level (53). Using metabolomics in two mouse models with complementary and well characterized spectrum of ß-cell defects, we identified the deoxyhexose 1,5-anhydroglucitol as a biomarker that closely associated with functional ß-cell mass preceding the appearance of hyperglycaemia. Specifically, the liver and plasma levels of 1,5-anhydroglucitol lowered along with functional ß-cell mass, through an unidentified mechanism, preceding diabetes onset and progressing further as diabetes manifested to a severe stage. Consistently, inverse association of deoxyhexose sugars with T2D has been reported about 6 years before T2D diagnosis in an untargeted study on a German cohort (54). In this cohort, the deoxyhexose levels were poorly correlated with other risk factors, such as age and body mass index (BMI) (54). In line with these results, a Korean study has shown that low serum levels of 1,5anhydroglucitol in euglycemic pre-diabetic subjects were associated with reduced insulinogenic index (a metric of insulin secretion capacity) and not with higher HOMA-IR (55). Regarding type 1 diabetes, a recent GC-MS analysis identified circulating metabolites in children who later progress to autoimmune diabetes, showing lower plasma levels of the sugar class 1,5-anhydrohexitol (e.g. 1,5anhydroglucitol) at 6 months of age compared to control subjects (56).
The deoxyhexose 1,5-anhydroglucitol has been previously reported as an index of short-term glycaemic control in T2D patients (57). Similar changes in 1,5-anhydroglucitol have been measured in ob/ob and db/db mice (58). In human cohorts, 1,5-anhydroglucitol has been reported to be 38% 16 lower in diabetic patients compared to control subjects (59) and the deoxyhexose correlated with impaired fasting glycemia and T2D (14; 15) . 1,5-Anhydroglucitol is a naturally occurring polyol found in nearly all foods and hardly metabolized in human (45) . It can also be synthesized from glycogen in the liver (60), although its de novo synthesis accounts for a small percentage of its whole body storage (61). The primary route for 1,5-anhydroglucitol disposal is urinary excretion, while hyperglycaemia has been shown to promote such a mechanism resulting in the lowering of plasma levels of 1,5-anhydroglucitol (45; 62). Indeed, 1,5-anhydroglucitol can be reabsorbed by the sodium/glucose co-transporter 4 (SGLT4) in the renal tubule (63) but its reabsorption is inhibited when blood glucose levels reach 10 mmol/L. Accordingly, it has been suggested that 1,5anhydroglucitol is sensitive in reflecting postprandial glycaemic excursions (64). The impaired glucose clearance in ß-Phb2 -/secondary to ß-cell failure (26) may contribute to reduced renal reabsorption of 1,5-anhydroglucitol and lowering of its plasma levels. In parallel, the decrease in hepatic 1,5-anhydroglucitol concentrations observed in ß-Phb2 -/mice could be the consequence of lower glycogen-derived biosynthesis, reducing its efflux normally occurring across the cell membrane (60; 65). These mechanisms may contribute to the lowering in plasma 1,5-anhydroglucitol levels, reflecting the progressive decline of the functional ß-cell mass in ß-Phb2 -/mice. Of note, we did not analyse the metabolome of the ß-cells since pancreata were fixed for the assessment of the ß-cell mass by immunohistochemistry in parallel to liver and plasma metabolomics. Therefore, the changes in liver and plasma 1,5-anhydroglucitol might be induced indirectly by the ß-cell decline, possibly by early modifications of hepatic metabolism in response to a pre-diabetic stage. Another constraint in our study was the limited amount of samples, in particular plasma volumes. We therefore focused on a single analytical metabolomics approach and negative mode ionization. In the future, the breadth of the analysis could be expanded by e.g. including positive mode ionization or complementary methods for the analysis of lipid extracts.
The vast heterogeneity of human genetics cannot be recapitulated in one mouse model, although investigating a highly heterogeneous background may introduce multiple confounding factors precluding the identification of a metabolite of significance. In order to reduce the putative impact of the genetic background and to widen the mechanisms promoting diabetes, we extended our analyses to db/db mice. They are characterized by ß-cell mass expansion (28; 29) as a sign of compensation for insulin resistance. However, such expansion of the insulin-positive cells does not prevent the development of hyperglycaemia, observed at the age of 8 weeks, as a consequence of ß-cell dysfunction. Glucose-stimulated calcium responses and insulin exocytosis are reduced in pre-diabetic db/db mice (30). The present study reveals similar changes in deoxyhexose levels in pre-diabetic db/db and ß-Phb2 -/mice, while being less pronounced in the former. BCAAs and aromatic amino acids are recognized predictors of insulin resistance (12; 66) . Accordingly, our data revealed higher increments of these amino acids in the plasma of overweight db/db mice compared to lean ß-Phb2 -/mice. These changes indicate that insulin resistance in db/db mice has a great impact on metabolome in pre-diabetes, not directly related to the ß-cell mass.
In conclusion, the common denominator for pre-diabetic db/db and ß-Phb2 -/mice was restricted to 1,5-anhydroglucitol, a sugar that can be easily measured by enzymatic-based colorimetric assay. This deoxyhexose reflects progressive decline of functional ß-cell mass at asymptomatic pre-diabetic stage.
Although this points to a valuable biomarker of early asymptomatic ß-cell decline, validation of our findings in human cohorts would be the ultimate goal. If combined with already known clinical risk factors, such as BMI and fasting glucose, such a biomarker could add value in predicting progression to T2D and to enable tailored treatment strategies. 19 17. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, Ryals JA, Milburn MV, Nannipieri M, Camastra S, Natali A, Ferrannini E, Group RS: alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 2010;5:e10883 18. Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari Values are expressed as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 between two groups.
Figure 2. Islet morphology and ß-cell mass in ß-Phb2 -/mice during diabetes development
(A) Representative pancreatic sections of immunofluorescence staining for insulin (green) and glucagon (red). Scale bar, 20 µm (applies to all panels).
(B) Representative pancreatic sections of immunohistochemistry for insulin using DAB (brown) in ß-Phb2 -/and control floxed mice. Scale bar, 20 µm (applies to all panels).
(C) Quantification of the ß-cell mass as defined by insulin-positive area (DAB staining from B) normalized to total pancreas weight (n=5-8).
(D) Plasma C-peptide concentrations (n=6).
(E) HOMA-IR index (n=6-11).
Values are expressed as mean ± SEM; *p<0.05, **p<0.01 between two groups. (B) Representative pancreatic sections of immunohistochemistry for insulin using DAB (brown) in db/db and control db/+ mice. Scale bar, 20 µm (applies to all panels).
(C) Quantification of the ß-cell mass as defined by insulin-positive area (DAB staining from B) normalized to total pancreas weight (n=4-6).
(E) HOMA-IR index (n=6).
Values are expressed as mean ± SEM; *p<0.05, **p<0.005 between two groups. (C) Differential analysis of amino acid and carbohydrate metabolism between ß-Phb2 -/and db/db mice with their respective controls at the each week of development. Color corresponds to log2 fold change ratios between them, while the size of the bubble corresponds to -log10 q-value (Student's ttest followed by multiple testing correction); n=6-9, see Supplementary Table S3 for detailed n numbers per group. Top metabolite name is included for each annotated ion, with m/z indicated. (B) Levels of deoxyhexose sugars in the liver and plasma of control db/+ mice (blue) and db/db mice (red) at different ages. *p<0.05, **p<0.01, ***p<0.001 between two groups.
Values in the boxplot are given as median, 25/75% percentiles (boxes), 10/90% percentiles (bars); *p<0.05, **p<0.01, ***p<0.001 between two groups. (C) Levels of fucose in the liver and plasma of control db/+ mice (blue) and db/db mice (red) at different ages.
GC-MS data in liver was normalized to n-docosane and fresh liver weight (maximum scaled [%]);
GC-MS data in plasma was calculated based on area (maximum scaled [%]); Values in the boxplot are given as median, 25/75% percentiles (boxes), 10/90% percentiles (bars); *p<0.05, **p<0.01, ***p<0.001 between two groups. analysis of amino acid and carbohydrate metabolism between ß-Phb2-/-and db/db mice with their respective controls at the each week of development. Color corresponds to log2 fold change ratios between them, while the size of the bubble corresponds to -log10 q-value (Student's t-test followed by multiple testing correction); n=6-9, see Supplementary Table S3 for detailed n numbers per group. Top metabolite name is included for each annotated ion, with m/z indicated.
198x277mm (300 x 300 DPI) Figure 5 . Boxplot of deoxyhexose sugars in the liver and plasma of ß-Phb2-/-and db/db mice Untargeted metabolomics by TOF-MS have identified a group of deoxyhexose sugars (m/z~163.061, in deprotonated form, C6H11O5). (A) Levels of deoxyhexose sugars in the liver and plasma of control Phb2fl/fl (blue) and ß-Phb2-/-mice (red) at different ages. (B) Levels of deoxyhexose sugars in the liver and plasma of control db/+ mice (blue) and db/db mice (red) at different ages. *p<0.05, **p<0.01, ***p<0.001 between two groups. Values in the boxplot are given as median, 25/75% percentiles (boxes), 10/90% percentiles (bars); *p<0.05, **p<0.01, ***p<0.001 between two groups.
217x220mm (300 x 300 DPI) Figure 6 . Boxplot of 1,5-anhydroglucitol in the liver and plasma of ß-Phb2-/-and db/db mice Targeted metabolomics by GC-MS annotated 1,5-anhydroglucitol as a potential biomarker. (A) Chemical structure of 1,5-anhydroglucitol. (B) Levels of 1,5-anhydroglucitol in the liver and plasma of control Phb2fl/fl mice (blue) and ß-Phb2-/-mice (red) at different ages. (C) Levels of 1,5-anhydroglucitol in the liver and plasma of control db/+ mice (blue) and db/db mice (red) at different ages. GC-MS data in liver was normalized to ndocosane and fresh liver weight (maximum scaled [%]); GC-MS data in plasma was calculated based on area (maximum scaled [%]); Values in the boxplot are given as median, 25/75% percentiles (boxes), 10/90% percentiles (bars); *p<0.05, **p<0.01, ***p<0.001 between two groups.
217x196mm (300 x 300 DPI) Figure 7 . Boxplot of fucose in the liver and plasma of ß-Phb2-/-and db/db mice Targeted metabolomics by GC-MS annotated fucose as a potential biomarker. (A) Chemical structure of fucose. (B) Levels of fucose in the liver and plasma of control Phb2fl/fl mice (blue) and ß-Phb2-/-mice (red) at different ages. (C) Levels of fucose in the liver and plasma of control db/+ mice (blue) and db/db mice (red) at different ages. GC-MS data in liver was normalized to n-docosane and fresh liver weight (maximum scaled [%]); GC-MS data in plasma was calculated based on area (maximum scaled [%]); Values in the boxplot are given as median, 25/75% percentiles (boxes), 10/90% percentiles (bars); *p<0.05, **p<0.01, ***p<0.001 between two groups.
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SUPPORTING INFORMATION
Metabolomics identifies a biomarker revealing in vivo loss of functional ß-cell mass before diabetes onset
Li et al. Table S1 . Primers for ß-Phb2 -/mice genotyping. Table S2 . Antibodies. Table S3 . Number of mice for mass spectrometry analysis. Table S4 . Glucose-stimulated insulin secretion from islets isolated from db/db mice. Phb2, mouse  Microsynth  5'ATC GTA TTG GTG GCG TGC AGC A-3'  5'CGA GGT CTG GCC CGA ATG TCA T-3'  5'AGG GAG GCT TGG TTT GAG GGG A-3'  Cre, mouse  Microsynth  5'TGC CAC GAC CAA GTG ACA GC-3'  5'CCA GGT TAC GGA TAT AGT TCA TG-3 ' (-)  100  7  88,03972506  7613,747472 L-Alanine; beta-A C00041; C00099; C00133; C00213; C01401; C01537; C02116; C11488  C3H7NO2  -H(-)  100  8  89,02377161  59809,28843 Glycerone; (S)-La C00184; C00186; C00256; C00577; C01013; C01432; C02154; C02426  C3H6O3  -H(-)  100  9  94,98004764  99746,19842 Methanesulfonic C11145  CH4SO3  -H(-)  100  10  95,04962958  2110,614107 Cyclohex-2-enon C02395; C19249  C6H8O  -H(-)  100  11  97,0289577  4931,395069 Furfuryl alcohol; C20441; C20578  C5H6O2  -H(-)  100  12  97,06517788  2353,482484 Cyclohexanone; ( C00414; C08497; C16310  C6H10O  -H(-)  100  13  99,00816076  3681,518959 Succinic anhydridC19524  C4H4O3  -H(-)  100  14  99,044662  4461,673271 5-Valerolactone; C02240; C08279; C12518; C14527; C15499; C19238  C5H8O2  -H(-)  100  15  101,0238857  10934,44956 2-Oxobutanoate C00109; C00164; C00232; C00349; C06002  C4H6O3  -H(-)  100  16  104,034911  2959,834334 L-Serine; Serine; DC00065; C00716; C00740  C3H7NO3  -H(-)  100  17  109,0403411  4704,000054 N-Acetylimidazol C02560; C05130  C5H6N2O  -H(-)  100  18  110,0243315  4734,594753 2,5-Dihydroxypy C01059; C02932; C03056; C03927; C05942  C5H5NO2  -H(-)  100  19  111,0083577  16267,8218 2-Furoate  C01546  C5H4O3  -H(-)  100  20  111,0195458  27374,22103 Uracil; Maleic hydC00106; C18474  C4H4N2O2  -H(-)  100  21  111,0447515  7885,039735 Cyclohexane-1,3 C01066; C04091; C04221; C06105; C08063; C08502  C6H8O2  -H(-)  100  22  112,0511765  2834,126678 Creatinine; 3-(N-C00791; C19280  C4H7N3O  -H(-)  100  23  113,023918  89783,13169 2-Hydroxy-2,4-p C00596; C07091  C5H6O3  -H(-)  100  24  113,0603514  14394,11062 2-Hydroxycycloh C01147; C01880; C03228  C6H10O2  -H(-)  100  25  114,0556408  28162,77814 L-Proline; D-Prol C00148; C00763; C16435; C18170  C5H9NO2  -H(-)  100  26  115,003352  44291,54972 Fumarate; Maleic C00122; C01384; C02150  C4H4O4  -H(-)  100  27  115,0396008  8768,735145 3-Methyl-2-oxob C00141; C02233; C03273; C06255  C5H8O3  -H(-)  100  28  115,076191  7229,728896 Hexanoic acid; 4-C01585; C02948; C03739; C12293; C12304; C12313  C6H12O2  -H(-)  100  29  116,0714197  57728,83369 L-Valine; 5-Amino C00183; C00431; C00719; C01799; C01826; C03571; C06417; C07457; C15987; C16436  C5H11NO2  -H(-)  100  30  117,0189068  103875,3201 Succinate; Methy C00042; C02170; C10900  C4H6O4  -H(-)  100  31  117,0553034  5067,857428 5-Hydroxypentan C02804; C20827  C5H10O3  -H(-)  100  32  118,0505817  13496,29231 L-Threonine; L-H C00188; C00263; C00820; C02115; C03678; C05519; C11108; C12317  C4H9NO3  -H(-)  100  33  118,9803863  131420,1402 Mercaptopyruva C00957  C3H4O3S  -H(-)  100  34  119,0345131  11433,59571 D-Erythrose; D-E C01796; C02022; C02045; C06463  C4H8O4  -H(-)  100  35  119,0498436  16223,19906 Phenylacetaldehy C00601; C02083; C05627; C06758; C07113; C07209; C07214; C20782  C8H8O  -H(-)  100  36  120,0662637  1162,027262 Tromethamine C07182  C4H11NO3  -H(-)  100  37  121,0294638  28837,16143 Benzoate; Aroma C00180; C00539; C00633; C03067; C06202; C15474  C7H6O2  -H(-)  100  38  121,0402954  21867,85269 Nicotinamide; Pic C00153; C01950; C02421  C6H6N2O  -H(-)  100  39  121,0654996  7129,396675 Phenylethyl alcoh C05853; C06757; C07112; C07213; C07216; C11348; C13637; C14385; C14386; C14582  C8H10O  -H(-)  100  40  122,0367111  5337,078158 Pyrazinamide  C01956  C5H5N3O  -H(-)  100  41  124,9906095  16498,71148 2-Hydroxyethane C05123; C19177  C2H6O4S  -H(-)  100  42  125,0234618  25452,11929 1,2,3-Trihydroxy C01108; C02183; C02752; C02814; C11101; C11918; C20718  C6H6O3  -H(-)  100  43  125,0604151  4990,347057 Toluene-cis-dihy C04592; C12101  C7H10O2  -H(-)  100  44  125,0968945  4284,643199 Sulcatone  C07287  C8H14O  -H(-)  100  45  127,0397587  8668,442567 Dihydro-4,4-dim C01125; C06719; C06761; C11354; C20240; C20443; C20717  C6H8O3  -H(-)  100  46  127,0509821  74910,70369 5,6-Dihydrothym C00906; C05715; C05717  C5H8N2O2  -H(-)  100  47  127,0760016  5637,358541 Ethyl tiglate; Cycl C08487; C09822; C10921; C10976; C11950; C13714; C13717  C7H12O2  -H(-)  100  48  128,0351706  102289,8145 4-Oxoproline; Pid C01877; C01879; C02237; C04281; C04282  C5H7NO3  -H(-)  100  49  129,0190549  12294,2253 2,5-Dioxopentan C00433; C00490; C01732; C02132; C02214; C02226; C02800  C5H6O4  -H(-)  100  50  129,0553951  11914,72253 4-Methyl-2-oxop C00233; C00671; C00902; C01012; C02122; C02129; C03241; C03465; C03467; C03500; C06008; C06102; C12314; C C6H10O3  -H(-)  100  51  129,0916905  8111,982484 Ethyl isovalerate; C12290; C12296; C17714  C7H14O2  -H(-)  100 
